IL6 and in situ carcinoma: The subsequent RuxCoFlam trial included COVID-19 patients with the same CIS cut-off (≥10) and yielded a similar response rate (71%), which was accompanied by a significant reduction of inflammation markers such as IFN-γ, IL-6, and IL-10 (p < 0.001 each) [9].